Mechanism-based inactivation of CYP2D6 by imperatorin and drug-drug interaction in vitro and in vivo

  • Arch Toxicol. 2026 Jul;100(7):2885-2897. doi: 10.1007/s00204-026-04367-2.
Hualu Wu  1  2 ,  Lu Cao  1 ,  Peiqi Wang  1 ,  Ruibin Li  1 ,  Jun Wu  1 ,  Haoxin Fu  1 ,  Yan Chen  1 ,  Shiqi Jiang  1 ,  Ren-Ai Xu  3  4
Affiliations
  • 1. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • 2. Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325035, China.
  • 3. The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. [email protected].
  • 4. Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325035, China. [email protected].
PMID: 41915188 DOI: 10.1007/s00204-026-04367-2
Keywords
CYP2D6; CYP3A4; Heraclenin; Imperatorin; Mechanism-based inactivation.
Products